• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

byConstance Wu
September 7, 2019
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In relatives of patients with type 1 diabetes (T1DM) at risk for disease development, randomization to teplizumab delayed time to T1DM diagnosis compared to placebo treated patients.

2. Adverse events associated with teplizumab treatment included rash and transient lymphopenia.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: T1DM results from autoimmune destruction of insulin-producing beta cells. Before frank insulin production deficits or dysglycemia arise autoantibodies are produced in patients at risk for T1DM. The Fc receptor-nonbinding anti-CD3 antibody teplizumab has been shown to reduce loss of beta cells after the diagnosis of T1DM, and whether is can slow progression to diagnosis in at-risk patients is unknown. This phase 2 randomized controlled trial showed a significant delay until T1DM diagnosis in high risk patients compared to placebo treated patients. Adverse events of rash and transient lymphopenia were observed in the treatment group. T-cells associated with unresponsiveness and downregulation of autoimmune activity were more common in teplizumab treated patients than those in the placebo group.

This randomized controlled trial suggests possible first-in-class efficacy of teplizumab for prophylactic delay of T1DM onset in high risk patients. The study is limited by the small trial size and its generalizability towards people at risk for T1DM without diagnosed first degree relatives is unknown.

Click to read the study in NEJM

RELATED REPORTS

Weekly insulin efsitora alfa is non-inferior to daily insulin degludec for reducing HbA1c in type 1 diabetes

Machine learning model non-invasively detects suspected cases of hypoglycemia during real-world driving

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: autoantibodyautoimmune diseaseteplizumabType 1 Diabetes Mellitus
Previous Post

The RELAX-AHF-2 trial: serelaxin provides no mortality benefit in acute heart failure patients

Next Post

#VisualAbstract: Liraglutide in Children and Adolescents with Type 2 Diabetes

RelatedReports

No benefit with hydroxychloroquine (Plaquenil) over placebo in Sjogren’s Syndrome [JOQUER Trial]
Chronic Disease

December 4, 2024
Dual VA and Medicare coverage linked to glucose strip overuse
Chronic Disease

Weekly insulin efsitora alfa is non-inferior to daily insulin degludec for reducing HbA1c in type 1 diabetes

October 9, 2024
Pediatric DKA associated with recent acute care visits
2 Minute Medicine

Machine learning model non-invasively detects suspected cases of hypoglycemia during real-world driving

September 13, 2024
#VisualAbstract: Teplizumab Improves β-cell Function in Newly Diagnosed Type 1 Diabetes
StudyGraphics

#VisualAbstract: Teplizumab Improves β-cell Function in Newly Diagnosed Type 1 Diabetes

April 30, 2024
Next Post
#VisualAbstract: Liraglutide in Children and Adolescents with Type 2 Diabetes

#VisualAbstract: Liraglutide in Children and Adolescents with Type 2 Diabetes

Breast cancer chemoprevention may reduce mortality in lobular carcinoma-in-situ

Quick Take: Breast Cancer Recurrence in the Nipple-Areola Complex After Nipple-Sparing Mastectomy With Immediate Breast Reconstruction for Invasive Breast Cancer

Eating in the absence of hunger linked to toddler obesity

Early childhood food insecurity linked to poor health and development, not obesity

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients
  • Rectoscopy alone may be sufficient to evaluate for remission of ulcerative colitis
  • Birth cohort effects observed for increased appendiceal adenocarcinoma incidence
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.